At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 81 enrolled
Drug / intervention
fostamatinibdrug
Likely dose
fostamatinib 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Multi-Center, Open Label Trial of the Safety and Efficacy of Fostamatinib in Patients With Relapsed/Refractory B-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating fostamatinib for Lymphoma. Completed, enrolled 81 participants across 11 sites.
Detailed Summary
Patients: B-cell lymphoma, refractory, diffuse, nodular, mantle, other Phase I : Two groups of 6 patients, escalating dose tolerability- 28 days Phase II: Three groups of 16 patients (nodular, diffuse large cell, mantle cell plus others). Oral bid dosing with highest tolerable dose until toxicity, progression, or withdrawal
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartApr 2007
Primary CompletionApr 2010
Study CompletionOct 2010
TodayJul 2026
First PostedMar 12, 2007
Enrollment StartApr 1, 2007
Primary CompletionApr 1, 2010
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 19.3 years ago
Interventions
fostamatinibdrug
200 mg PO BID